Eli Lilly said its second-quarter profit slid 39% as patent expirations for some of its bigger-selling drugs dragged down revenue and volume.
WSJ.com: What's News US, Wall Street Journal
Thu, 07/24/2014 - 4:16am
Eli Lilly said its second-quarter profit slid 39% as patent expirations for some of its bigger-selling drugs dragged down revenue and volume.